Skip to main content
SpringerLink
Log in

PET/CT Findings in Renal Cancer

  • Chapter
  • First Online:
Imaging in Clinical Oncology

  • 1629 Accesses

Abstract

The incidence of renal cell carcinoma (RCC) at all stages is rising, with clear cell histologic type being the commonest [1]. However, it has been reported that 15% of small renal masses are benign [2]. Partial or total nephrectomy is the current treatment for RCC. Contrast-enhanced computed tomography (CECT)-renal protocol [3] is the imaging modality of choice in detection and differentiation of solid renal masses versus cystic ones, even small ones of size <2 cm; however, it faces certain limitations consisting of its lower ability to differentiate between benign and malignant lesions, as well as indolent from aggressive phenotype [2, 3]. The role of magnetic resonance imaging (MRI) is currently mostly restricted to characterization of equivocal computed tomography (CT) findings, evaluation of perirenal fat, and venous cava thrombosis. The urge of functional characterization of renal masses has brought the utilization of PET/CT at the foreground [2, 3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cairns P (2011) Renal cell carcinoma. Cancer Biomark 9(1–6):461–473

    Article  Google Scholar 

  2. Smaldone MC, Chen DY, Yu JQ, Plimack ER (2012) Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics 6:395–407

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Khandani AH, Rathmell WK (2012) Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Semin Nucl Med 42(4):221–230

    Article  Google Scholar 

  4. Lawrentschuk N, Davis ID, Bolton DM, Scott AM (2010) Functional imaging of renal cell carcinoma. Nat Rev Urol 7(5):258–266

    Article  Google Scholar 

  5. Takahashi M, Kume H, Koyama K et al (2015) Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT. Clin Nucl Med 40(12):936–940

    Article  Google Scholar 

  6. Ramdave S, Thomas GW, Berlangieri SU et al (2001) Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 166(3):825–830

    Article  CAS  Google Scholar 

  7. Aide N, Cappele O, Bottet P et al (2003) Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur J Nucl Med Mol Imaging 30(9):1236–1245

    Article  Google Scholar 

  8. Ozülker T, Ozülker F, Ozbek E, Ozpaçaci T (2011) A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses. Nucl Med Commun 32(4):265–272

    Article  Google Scholar 

  9. Kang DE, White RL Jr, Zuger JH et al (2004) Emission tomography for detection of renal cell carcinoma. J Urol 171(5):1806–1809

    Article  Google Scholar 

  10. Wu HC, Yen RF, Shen YY et al (2002) Comparing whole body 18F–2-deoxyglucose positron emission tomography and technetium-99 m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas: a preliminary report. J Cancer Res Clin Oncol 128(9):503–506

    Article  CAS  Google Scholar 

  11. Kayani I, Avril N, Bomanji J et al (2011) Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 17(18):6021–6028

    Article  CAS  Google Scholar 

  12. Namura K, Minamimoto R, Yao M et al (2010) Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 10:667

    Article  Google Scholar 

  13. Misch D, Steffen IG, Schönberger S et al (2008) Use of positron emission tomography for staging, preoperative response assessment and posttherapeutic evaluation in children with Wilms tumour. Eur J Nucl Med Mol Imaging 35(9):1642–1650

    Article  Google Scholar 

  14. Nakatani K, Nakamoto Y, Saga T et al (2011) The potential clinical value of FDG-PET for recurrent renal cell carcinoma. Eur J Radiol 79(1):29–35

    Article  Google Scholar 

  15. Park JW, Jo MK, Lee HM (2009) Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma. BJU Int 103(5):615–619

    Article  Google Scholar 

  16. Safaei A, Figlin R, Hoh CK et al (2002) The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer. Clin Nephrol 57(1):56–62

    Article  CAS  Google Scholar 

  17. Kumar R, Shandal V, Shamim SA et al (2010) Role of FDG PET-CT in recurrent renal cell carcinoma. Nucl Med Commun 31(10):844–850

    PubMed  Google Scholar 

  18. Alongi P, Picchio M, Zattoni F et al (2016) Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging 43(3):464–473

    Article  CAS  Google Scholar 

  19. Nakaigawa N, Kondo K, Tateishi U et al (2016) FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. BMC Cancer 16:67

    Article  Google Scholar 

  20. Ueno D, Yao M, Tateishi U et al (2012) Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 12:162

    Article  Google Scholar 

  21. Divgi CR, Pandit-Taskar N, Jungbluth AA et al (2007) Preoperative characterisation of clear- cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol 8(4):304–310

    Article  CAS  Google Scholar 

  22. Divgi CR, Uzzo RG, Gatsonis C et al (2013) Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 31(2):187–194

    Article  Google Scholar 

  23. Gerety EL, Lawrence EM, Wason J et al (2015) Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design. Ann Oncol 26(10):2113–2118

    Article  CAS  Google Scholar 

  24. Hugonnet F, Fournier L, Medioni J et al (2011) Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: an 18F- Fluoromisonidazole PET/CT study. J Nucl Med 52:1048–1055

    Article  Google Scholar 

  25. Liu G, Jeraj R, Vanderhoek M et al (2011) Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res 17(24):7634–7644

    Article  CAS  Google Scholar 

  26. Middendorp M, Maute L, Sauter B et al (2010) Initial experience with 18F-fluoroethylcholine PET/ CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med 24(6):441–446

    Article  CAS  Google Scholar 

  27. Horn KP, Yap JT, Agarwal N et al (2015) FDG and FLT-PET for early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging 15:15

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Physiology Department, Kanta-Hame Central Hospital, Hameenlinna, Finland

    Alexandra V. Nikaki

  2. Nuclear Medicine and PET/CT Department, Hygeia Hospital, Athens, Greece

    Alexandra V. Nikaki

Authors
  1. Alexandra V. Nikaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, National and Kapodistrian, University of Athens, Athens, Greece

    Athanasios D. Gouliamos

  2. Imaging Department, Hygeia and Mitera Hospitals, Athens, Greece

    John A. Andreou

  3. Medical Oncologist, Head, Medical Oncology Department, Hygeia Hospital, Athens, Greece

    Paris A. Kosmidis

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Nikaki, A.V. (2018). PET/CT Findings in Renal Cancer. In: Gouliamos, A., Andreou, J., Kosmidis, P. (eds) Imaging in Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-68873-2_76

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68873-2_76

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68872-5

  • Online ISBN: 978-3-319-68873-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation